Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05395052 · ClinicalTrials.gov registry record · Phase 1
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05395052 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT05395052, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG IL-2
- DRUG FT536
- COMBINATION_PRODUCT Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05395052
The ClinicalTrials.gov registry entry for NCT05395052 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05395052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05395052 about?
NCT05395052 is a clinical study titled "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors". This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific co...
What is the current status of trial NCT05395052?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-05-31. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT05395052?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), FT536 (DRUG), Avelumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05395052?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.